Panacea Biotec: Sunil Anand superannuates as Associate Director - Finance & Corporate Affairs
New Delhi: Panacea Biotec has announced that Sunil Anand, Associate Director - Finance & Corporate Affairs of the Company, designated as Senior Management Personnel, has superannuated from the services of the Company on March 31, 2025 after having served the Company as a Whole-time Director / Associate Director for over two decades.
Consequently Sunil Anand has ceased to be a Senior Management Personnel on March 31, 2025.
"The Management of the Company express deep appreciation and gratitude to the aforesaid senior management personnel for his extensive contribution and guidance towards the business growth of the Company, during his long association with the Company," Panacea stated in a BSE filing.
Read also: ICMR, Panacea Biotec begin first ever Phase 3 clinical trial for dengue vaccine in India
In addition to Anand’s retirement,, the Company has also announced that Manjula Upadhyay, Independent Director of the Company, has completed her second and final term of five consecutive years as Independent Director on March 29, 2025 and consequently she has ceased to be the director of the Company.
Panacea Biotec is an innovation-driven Biotechnology company doing Research and Development, Manufacturing, Sales, Distribution and Marketing of Pharmaceuticals and Vaccines.
Panacea Biotec was set up in the year 1984, under the name of Panacea Drugs Private Limited. It got publically listed on Indian National Stock Exchanges in September 1995 as Panacea Biotec Ltd. The international pharmaceutical formulations product portfolio includes innovative prescription products in niche therapeutic areas such as Pain, Diabetes & Cardiovascular management, Oncology, Renal Disease, Osteoporosis management and Gastro-intestinal care.
